Hyperuricemia in 2025: Epidemiology, Mechanisms, Associated Conditions and Treat-to-target Management
Indian Journal of Rheumatology · 20.08.2026
DOI: 10.1177/09733698261473347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Rheumatology, online erschienen am 20.08.2026. Verfasst von Onkaramurthy Mallappa und 3 weiteren Autor:innen. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hyperuricemia has moved from a niche biochemical finding to a clinically relevant cardio-renal-metabolic risk state. This review synthesises contemporary evidence on uric acid biology, epidemiology, and management. We outline sources and biochemistry of urate, the hepatic xanthine oxidoreductase pathway, and the coordinated roles of renal and intestinal transporters that set steady-state serum levels, emphasising URAT1, GLUT9, NPT1, NPT4, and ABCG2, as well as the organic anion transporters OAT1 and OAT3, which import uric acid from the blood into proximal tubule cells. We summarise definitions, diagnostic thresholds, and global prevalence with sex-specific ranges, then differentiate asymptomatic hyperuricemia from crystal disease. Clinical sections integrate mechanistic links between soluble and crystalline urate and organ injury: inflammasome-mediated gout; tubulointerstitial injury, arteriolopathy, and obstructive pathways in kidney disease; oxidative stress, endothelial dysfunction, and vascular remodelling in hypertension, atherosclerosis, and coronary events; and metabolic pathways involving fructose metabolism, insulin resistance, and hepatic lipogenesis that connect hyperuricemia to metabolic syndrome and MAFLD. We appraise clinical evidence across cohorts, imaging, genetics, and randomised trials, distinguishing strong causal domains such as gout and uric acid nephrolithiasis from associative domains where treatment decisions should be individualised. A practical, phenotype-driven treat-to-target framework is presented that prioritises xanthine oxidase inhibition, adds uricosuric therapy for underexcretion, embeds lifestyle therapy, and applies safety strategies including HLA-B*58:01 screening in high-risk ancestries. We conclude with research gaps and priorities, including transporter-targeted strategies, intestinal urate quantification, pragmatic trials in enriched phenotypes, and clarity on long-term cardiovascular and renal outcomes.
Zitieren
APA
Mallappa, O., Mukhram, M. A., Nayak, Y., & Rafiq, M. (2026). Hyperuricemia in 2025: Epidemiology, Mechanisms, Associated Conditions and Treat-to-target Management. Indian Journal of Rheumatology. https://doi.org/10.1177/09733698261473347
Vancouver
Mallappa O, Mukhram MA, Nayak Y, Rafiq M. Hyperuricemia in 2025: Epidemiology, Mechanisms, Associated Conditions and Treat-to-target Management. Indian Journal of Rheumatology. 2026. doi:10.1177/09733698261473347
BibTeX
@article{Mallappa2026,
author = {Mallappa, Onkaramurthy and Mukhram, Mohammed Azeemuddin and Nayak, Yogendra and Rafiq, Mohamed},
title = {Hyperuricemia in 2025: Epidemiology, Mechanisms, Associated Conditions and Treat-to-target Management},
journal = {Indian Journal of Rheumatology},
year = {2026},
doi = {10.1177/09733698261473347}
}
EUVIMED